Want to see GB:BSFA full AI Analyst Report?
BSF Enterprise PLC (BSFA) AI Stock Analysis
BSF Enterprise PLC
(LSE:BSFA)
The overall score is heavily pressured by weak financial performance and a negative P/E ratio, reflecting a pre-revenue, loss-making company. The primary positive is a debt-free balance sheet, which provides some stability. Technicals show short-term momentum improvement, but the stock remains in a longer-term downtrend. The lack of profitability and ongoing cash burn are the most significant risks.
BSF Enterprise PLC (BSFA) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 11.55K
- Dividend Yield
- ―
- Average Volume (3M)
- 2.89M
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 3.61
- Revenue Growth
- 112.02%
- EPS Growth
- 31.51%
- Country
- UK
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BSF Enterprise PLC Business Overview & Revenue Model
Company Description
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company develops and commercializes cell-based tissue engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. The principal activity of the...
BSF Enterprise PLC Financial Statement Overview
Summary
Financial performance is weak but shows marginal improvement. Revenue is minimal and declining, gross profit is negative, and net losses persist. However, operating and net losses have narrowed, and the balance sheet is debt-free with positive equity. Cash burn is improving but remains a significant concern. Overall, the company is not yet financially sustainable.
Income Statement
20Very NegativeBalance Sheet
40NegativeCash Flow
25Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.06K | 52.84K | 57.82K | 12.94K | 0 | 0 |
| Gross Profit | -125.04K | -127.47K | -26.64K | -86.55K | -160.50K | 0 |
| EBITDA | -1.33M | -1.10M | -1.68M | -1.46M | -905.76K | 0 |
| Net Income | -1.28M | -1.11M | -1.67M | -1.50M | -930.04K | -58.43K |
Balance Sheet | ||||||
| Total Assets | 3.47M | 3.01M | 3.50M | 5.26M | 4.03M | 401.45K |
| Cash, Cash Equivalents and Short-Term Investments | 60.17K | 149.02K | 637.66K | 2.32M | 1.06M | 359.87K |
| Total Debt | 482.32K | 0 | 78.05K | 156.93K | 231.88K | 0 |
| Total Liabilities | 1.71M | 289.02K | 305.07K | 401.63K | 449.47K | 36.63K |
| Stockholders Equity | 1.76M | 2.72M | 3.19M | 4.86M | 3.58M | 364.82K |
Cash Flow | ||||||
| Free Cash Flow | -642.81K | -1.02M | -1.60M | -1.44M | -677.86K | -85.19K |
| Operating Cash Flow | -600.62K | -1.01M | -1.59M | -1.38M | -667.24K | -85.19K |
| Investing Cash Flow | -41.76K | -9,916 | -12.02K | -64.85K | 1,750 | 0 |
| Financing Cash Flow | 363.60K | 529.69K | -78.88K | 2.70M | 1.37M | 0 |
BSF Enterprise PLC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BSFA, the sentiment is Negative. The current price of 0.90 is below the 20-day moving average (MA) of 1.04, below the 50-day MA of 1.05, and below the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 22.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BSFA.
BSF Enterprise PLC Peers Comparison
Overall Rating
- GB:BSFA44Neutral
GB:BLU43Neutral
GB:PRIM40Underperform
GB:MFAI39Underperform
GB:TRUE38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:BSFA | 44Neutral | GBP 1.83M | -0.91 | -57.16% | ― | 112.02% | 31.51% |
| GB:BLU | 43Neutral | GBP 2.17M | -1.51 | -43.66% | ― | ― | 83.53% |
| GB:PRIM | 40Underperform | GBP 4.22M | 3.12 | 22.69% | ― | ― | ― |
| GB:MFAI | 39Underperform | GBP 1.97M | -0.28 | -54.65% | ― | 2950.00% | -273.53% |
| GB:TRUE | 38Underperform | GBP 1.77M | -4.09 | -17.10% | ― | ― | 68.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:BSFA | BSF Enterprise PLC | 0.90 | -2.25 | -71.43% | |
| GB:BLU | Blue Star Capital | 4.25 | -7.25 | -63.04% | |
| GB:TRUE | Braveheart Investment | 2.25 | 0.15 | 7.14% | |
| GB:MFAI | Pires Investments | 0.25 | -0.50 | -66.67% | |
| GB:PRIM | Primorus Investments | 3.40 | -0.50 | -12.82% | |
| GB:CGO | Contango Holdings Plc | 0.70 | -0.23 | -24.32% |
BSF Enterprise PLC Corporate Events
BSF Enterprise Wins Key US Patent for Macromolecular Crowding Media
PositiveBSF Enterprise’s subsidiary 3D Bio-Tissues has received a US Notice of Allowance for a patent covering serum-free and reduced-serum cell culture media using macromolecular crowding agents for skin and corneal cells. The patent, with 17 allowed...
BSF Enterprise Reshapes Group Structure Around 3D Bio-Tissues and New milieu.bio Subsidiary
PositiveBSF Enterprise PLC has initiated a strategic corporate reorganisation that positions 3D Bio-Tissues as the group’s central intellectual property and manufacturing hub, while converting its Cultivated Meat Technologies unit into milieu.bio, a de...
BSF Enterprise Secures Key U.S. Patent for ETSYL Collagen Technology
PositiveBSF Enterprise’s subsidiary 3D Bio-Tissues has secured a Notice of Allowance from the U.S. Patent and Trademark Office for its ETSYL-branded collagen production technology, protecting proprietary methods that use the bioactive peptide palmitoyl...
BSF Enterprise Gains FCA Approval for Prospectus to Support Warrant Exercises and Share Admission
PositiveBSF Enterprise PLC has secured approval from the Financial Conduct Authority for a new prospectus that establishes a long-term regulatory framework for the potential exercise of existing warrants and convertible securities over the next 12 months. Th...
BSF Enterprise reduces debt as Indigo converts £100k of loan notes into shares
PositiveBSF Enterprise PLC has received a notice from Indigo Capital Investments to convert £100,283 of its £1m convertible loan notes into equity. The company will satisfy the conversion by issuing 10,000,000 new ordinary shares of 1 penny each to...
BSF Enterprise strikes SCHAKAU deal to push lab-grown leather into ultra-luxury cars and robotics
PositiveBSF Enterprise has signed a strategic partnership with German consultancy SCHAKAU Managementberatung to commercialise its lab-grown leather in the ultra-luxury European automotive market and to advance biological human-interface technologies for robo...
BSF Enterprise Grants Global Exclusive Rights to ETSYL Peptide in Luxury Skincare Deal
PositiveBSF Enterprise PLC has signed heads of terms for a worldwide, exclusive commercialisation and supply partnership for its proprietary bioactive peptide ETSYL with SCHAKAU Managementberatung GmbH in the cosmetics and luxury beauty sectors. SCHAKAU is p...
BSF Enterprise Strikes US Joint Venture to Launch T-Rex Leather in Luxury Market
PositiveBSF Enterprise PLC has signed non-binding Heads of Terms with US ethical luxury brand operator IMPOSTER LLC to form a 50/50 joint venture aimed at launching its T-Rex Leather in the North American luxury market. The JV will initially focus on small n...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 18, 2026